ストックスクリーナーアプリを入手
2.28
1.79%
0.04
アフターアワーズ：
2.29
0.01
+0.44%
前日終値:
$2.24
開ける：
$2.24
24時間の取引高:
2.10M
Relative Volume:
1.48
時価総額：
$394.08M
収益：
-
当期純損益:
$-54.70M
株価収益率:
-6.9091
EPS:
-0.33
ネットキャッシュフロー:
$-51.36M
1週間 パフォーマンス:
-19.72%
1か月 パフォーマンス:
-30.06%
6か月 パフォーマンス:
-32.14%
1年 パフォーマンス:
-44.53%
1日の値動き範囲:
$2.18
$2.40
1週間の範囲:
$1.89
$2.40
52週間の値動き範囲:
$1.89
$5.11
Savara Inc Stock (SVRA) Company Profile
SVRA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
2.28 | 490.86M | 0 | -54.70M | -51.36M | -0.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | 開始されました | Wells Fargo | Overweight |
| 2024-11-13 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-15 | 開始されました | JMP Securities | Mkt Outperform |
| 2023-11-07 | 開始されました | Guggenheim | Buy |
| 2023-05-16 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-31 | ダウングレード | Jefferies | Buy → Hold |
| 2021-03-16 | 開始されました | Piper Sandler | Overweight |
| 2021-03-15 | 開始されました | Oppenheimer | Outperform |
| 2019-06-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-13 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | 再開されました | ROTH Capital | Neutral |
| 2018-01-03 | 開始されました | Ladenburg Thalmann | Buy |
| 2017-09-27 | 再開されました | ROTH Capital | Buy |
| 2017-09-22 | 開始されました | Jefferies | Buy |
| 2017-09-11 | 開始されました | JMP Securities | Mkt Outperform |
すべてを表示
Savara Inc (SVRA) 最新ニュース
Savara Inc (NASDAQ:SVRA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
What is HC Wainwright’s Forecast for Savara FY2029 Earnings? - Defense World
Did Savara Inc. (SVRA) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
FDA Denies Langhorne-Based Savara Application for Rare Lung Disease Treatment - MSN
Savara Inc. Grants Equity Awards to New Employees - MSN
Savara Inc. to Present at Jefferies Global Healthcare Conference on June 4, 2025 - MSN
Savara stock rating cut to Neutral by H.C. Wainwright - Investing.com Nigeria
This Starbucks Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
HC Wainwright Downgrades Savara to Neutral From Buy, Adjusts Price Target to $2 From $6 - marketscreener.com
SVRA: Savara Downgraded by HC Wainwright & Co. | SVRA Stock News - GuruFocus
H.C. Wainwright Lowers Savara (SVRA) Outlook Following FDA Setba - GuruFocus
H.C. Wainwright Lowers Savara (SVRA) Outlook Following FDA Setback | SVRA Stock News - GuruFocus
Savara stock price target cut to $2 at Evercore ISI By Investing.com - Investing.com Canada
Savara Inc (NASDAQ:SVRA) Shares Bought by D. E. Shaw & Co. Inc. - Defense World
Guggenheim Reaffirms “Buy” Rating for Savara (NASDAQ:SVRA) - Defense World
Savara (NASDAQ:SVRA) Given New $2.00 Price Target at Evercore ISI - Defense World
Savara (NASDAQ:SVRA) Price Target Lowered to $7.00 at Wells Fargo & Company - Defense World
SVRA ALERT: Levi & Korsinsky Investigates Savara Inc. on Behalf of Shareholders Who Lost Money - ACCESS Newswire
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc.SVRA - Bluefield Daily Telegraph
Key Analyst Rating Update for Savara (SVRA) | SVRA Stock News - GuruFocus
Savara stock price target cut to $2 at Evercore ISI - Investing.com Australia
Savara (SVRA) Stock Rating Maintained, Price Target Adjusted | S - GuruFocus
Savara (SVRA) Stock Rating Maintained, Price Target Adjusted | SVRA Stock News - GuruFocus
FDA refuses to file Savara BLA for Molbreevi - The Pharma Letter
Wells Fargo Maintains Overweight Rating on Savara (SVRA) with Lower Price Target | SVRA Stock News - GuruFocus
Savara (SVRA) Faces Lowered Price Target Amid BLA Challenges | S - GuruFocus
Guggenheim cuts Savara stock target to $8, maintains Buy rating By Investing.com - Investing.com India
Guggenheim cuts Savara stock target to $8, maintains Buy rating - Investing.com
Savara Inc (NASDAQ:SVRA) Shares Purchased by BNP Paribas Financial Markets - Defense World
Wells Fargo Adjusts Savara (SVRA) Price Target Following FDA Feedback | SVRA Stock News - GuruFocus
SVRA stock touches 52-week low at $1.91 amid market challenges By Investing.com - Investing.com South Africa
Manufacturing issues scupper Savara's lead drug filing - pharmaphorum
SVRA stock touches 52-week low at $1.91 amid market challenges - Investing.com India
Savara’s SWOT analysis: molbreevi’s potential drives stock outlook - Investing.com India
INVESTOR ALERT: Investigation of Savara Inc. (SVRA) Announced by Holzer & Holzer, LLC - GlobeNewswire
Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday? - Benzinga
Savara stock dives after FDA refuses filing for rare lung disease drug - FirstWord Pharma
Savara stock plummets after FDA issues 'refuse to file' letter for lead drug candidate Molbreevi - The Business Journals
Biogen strikes RNAi deal with City; Aurion withdraws IPO - BioPharma Dive
BREAKING: Savara Shares Down Over 30%; Securities Fraud Investigation by Block & Leviton ... - Bluefield Daily Telegraph
BREAKING: Savara Shares Down Over 30%; Securities Fraud - GlobeNewswire
FDA calls for additional manufacturing data in refusal letter for Savara's respiratory asset - Fierce Pharma
FDA seeks additional data for Savara’s MOLBREEVI BLA By Investing.com - Investing.com South Africa
Savara (SVRA) Faces FDA Setback on Molbreevi Therapy | SVRA Stoc - GuruFocus
Savara (SVRA) Faces FDA Hurdles on Molbreevi Application - GuruFocus
Savara Receives FDA Refusal to File Letter for BLA of Potential Autoimmune PAP Therapy; Shares Fall Pre-Bell - marketscreener.com
Savara receives RTF letter from FDA for Molbreevi BLA - TipRanks
Savara Receives Refusal to File (RTF) Letter From the U.S. Food - GuruFocus
Savara Faces FDA Setback for MOLBREEVI Application - TipRanks
Savara marketing application found to be incomplete (SVRA:NASDAQ) - Seeking Alpha
Savara Inc (SVRA) 財務データ
収益
当期純利益
現金流量
EPS
1.89%
3.74%
大文字化:
|
ボリューム (24 時間):